SCHEMBL4519986

SCHEMBL4519986

CCOc1nc(N)nc2ccc(-c3ccc(Cl)s3)nc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TP53 P04637 2/20 0.35
MAP4K4 O95819 1/20 0.34
ALDH1A1 P00352 6/20 0.34
KMT2A Q03164 2/20 0.34
HSD17B10 Q99714 2/20 0.34
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
CCR4 P51679 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
PDGFRB P09619 1/20 0.33
PDGFRA P16234 1/20 0.33
KDM1A O60341 1/20 0.33
AGPAT2 O15120 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4521264 0.82 MAPK8 (0.37) KDM4ETP53MAP4K4ALDH1A1HSD17B10
SCHEMBL3756730 0.81 NOS1 (0.39) KDM4EHPGDSMN1; SMN2TP53CCR4
SCHEMBL823646 0.81 SMN1; SMN2 (0.39) KDM4EHPGDSMN1; SMN2TP53ALDH1A1
SCHEMBL4533141 0.80 KDM4E (0.46) KDM4EHPGDSMN1; SMN2ALDH1A1KMT2A
SCHEMBL4529751 0.80 MAP4K4 (0.44) KDM4EHPGDSMN1; SMN2TP53MAP4K4
SCHEMBL4529758 0.79 KDM1A (0.39) KDM4ETP53ALDH1A1KMT2AHSD17B10
SCHEMBL4528297 0.79 MAP4K4 (0.49) KDM4EHPGDSMN1; SMN2MAP4K4ALDH1A1
SCHEMBL823750 0.78 ALDH1A1 (0.34) KDM4EHPGDSMN1; SMN2TP53ALDH1A1
SCHEMBL4522776 0.78 L3MBTL1 (0.54) KDM4EMAP4K4ALDH1A1L3MBTL1MAPT
SCHEMBL4524543 0.77 MAPT (0.55) KDM4EMAP4K4L3MBTL1MAPTAGPAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232278-B2 Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C GILEAD SCIENCES, INC. (US) 2012-07-31 US claimed
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C GILEAD SCIENCES, INC. (US) 2009-05-21 US claimed
US-8232278-B2 Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C GILEAD SCIENCES, INC. (US) 2012-07-31 US disclosed
US-8232278-B2 Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C GILEAD SCIENCES, INC. (US) 2012-07-31 US disclosed
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C GILEAD SCIENCES, INC. (US) 2009-05-21 US disclosed
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C GILEAD SCIENCES, INC. (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C DPYD, TYMP, PNPO KDM4E 3685/4885HPGD 119/4885SMN1; SMN2 2873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.